Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN), a biopharmaceutical company focused on antibody-drug conjugates (ADCs), announced that CEO Anna Protopapas will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 3:20 p.m. ET. Investors can access a live webcast on Mersana's website, with an archived replay available for 90 days post-event. Mersana is developing innovative ADCs to improve cancer treatment, with its lead candidate, upifitamab rilsodotin (UpRi), targeting platinum-resistant ovarian cancer.

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 3:20 p.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the event.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com

FAQ

When is Mersana Therapeutics presenting at the Stifel 2021 Virtual Healthcare Conference?

Mersana Therapeutics will present on November 17, 2021, at 3:20 p.m. ET.

Where can I watch the Mersana Therapeutics conference presentation?

You can watch the live webcast on Mersana's website in the Investors & Media section.

What is Mersana Therapeutics' lead product candidate?

Mersana's lead product candidate is upifitamab rilsodotin (UpRi), targeting platinum-resistant ovarian cancer.

How long will the Mersana conference presentation be available for replay?

The archived replay of the presentation will be available for approximately 90 days.

What type of therapies is Mersana Therapeutics developing?

Mersana Therapeutics focuses on antibody-drug conjugates (ADCs) for cancer treatment.